In yesterday’s Wall Street session, IVERIC bio Inc. (NASDAQ:ISEE) shares traded at $37.05, down -1.49% from the previous session.
11 analysts cover IVERIC bio Inc. (NASDAQ:ISEE), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $40.00 and a low of $40.00, we find $40.00. Given the previous closing price of $37.61, this indicates a potential upside of 6.35 percent. ISEE stock price is now 28.87% away from the 50-day moving average and 72.54% away from the 200-day moving average. The market capitalization of the company currently stands at $5.07B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
The stock has received a hold rating from 11 analysts and a buy rating from 0. Brokers who have rated the stock have averaged $40.00 as their price target over the next twelve months.
On November 10, 2022, Jefferies Downgraded its previous ‘Buy’ rating to ‘Hold’ on the stock reducing its target price from $30 to quote $20, while ‘B. Riley Securities’ rates the stock as ‘Neutral’.
In other news, Westby Keith, SVP, Chief Operating Officer sold 20,000 shares of the company’s stock on May 02. The stock was sold for $756,200 at an average price of $37.81. Upon completion of the transaction, the SVP, Chief Operating Officer now directly owns 39,652 shares in the company, valued at $1.47 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 01, SVP, Chief Financial Officer Carroll David Francis sold 63,500 shares of the business’s stock. A total of $2,352,040 was realized by selling the stock at an average price of $37.04. This leaves the insider owning 68,472 shares of the company worth $2.54 million. Insiders disposed of 377,786 shares of company stock worth roughly $14.0 million over the past 1 year. A total of 0.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ISEE stock. A new stake in IVERIC bio Inc. shares was purchased by HOLOCENE ADVISORS, LP during the first quarter worth $73,969,000. WESTFIELD CAPITAL MANAGEMENT CO LP invested $17,663,000 in shares of ISEE during the first quarter. In the first quarter, FEDERATED HERMES, INC. acquired a new stake in IVERIC bio Inc. valued at approximately $17,414,000. DUQUESNE FAMILY OFFICE LLC acquired a new stake in ISEE for approximately $14,820,000. ARTISAN PARTNERS LIMITED PARTNERSHIP purchased a new stake in ISEE valued at around $11,527,000 in the second quarter. In total, there are 315 active investors with 96.20% ownership of the company’s stock.
On Tuesday morning IVERIC bio Inc. (NASDAQ: ISEE) stock kicked off with the opening price of $37.07. During the past 12 months, IVERIC bio Inc. has had a low of $8.85 and a high of $38.25. As of last week, the company has a debt-to-equity ratio of 0.20, a current ratio of 15.50, and a quick ratio of 15.50. The fifty day moving average price for ISEE is $29.03 and a two-hundred day moving average price translates $21.61 for the stock.
The latest earnings results from IVERIC bio Inc. (NASDAQ: ISEE) was released for Mar, 2023.
IVERIC bio Inc.(ISEE) Company Profile
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
